OBJECTIVES Rheumatic diseases (RD) have been associated with functional and work-related disability due to the deliberating and progressive nature of these diseases and have many deleterious consequences on patients' lifeThe aim of the present study was to measure the functional status and quality of life in RD patients receiving the biologic agent golimumab in Greece METHODS A descriptive study was conducted estimating the annual Quality-of-Life (QoL) improvement for 148 patients diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PS) and ankylosing spondylitis (AS). QoL was estimated with standardized questionnaires such as EQ-5D and HAQ questionnaire. In addition, twenty specific parameters including “general health”, “severity of pain”, “productivity level” etcetera wereassessed on  10-point Likert scale. Data was collected by doctors across the country at 3 month intervals (4 waves of questionnaires during the year).  RESULTS Patients with RA reported improved QoL by 14%, followed by 0.67 decrease of average HAQ score. They also reported a 7.5 hours gain of working hours and an overall 14% gain in productivity per week. Patients with AS were estimated to present 30% improvement in general health condition according to their doctors with similar self-reported estimations. Additionally, their QoL was improved by 17%. Similarly, patients with PS estimated their QoL improved by 17% with a 6hr/week gain in working hours otherwise missed, while the average HAQ score fell by 0.71 Findings are in accordance with similar published studies all contributing to the general assumption that patients receiving biological agents experience greater QoL improvement compared to conservative treatment options.  CONCLUSIONS Statistical analysis revealed significant improvement of functional status, quality of life, productivity gains and decrease of disease activity for those receiving Golimumab in Greece for all three disease groups. Amongst limitations, both number of the study group and follow-up period should be taken into consideration.